Balancing the benefits and risks of inhaled long-acting beta-agonists—the influence of values
JM Kramer - New England Journal of Medicine, 2009 - Mass Medical Soc
JM Kramer
New England Journal of Medicine, 2009•Mass Medical SocIn December 2008, the FDA reviewed the risks and benefits of inhaled long-acting beta-
agonists for the treatment of asthma in adults and children. Dr. Judith Kramer writes that the
challenge of protecting the public's health is heightened by variability in the values placed
on benefits and risks.
agonists for the treatment of asthma in adults and children. Dr. Judith Kramer writes that the
challenge of protecting the public's health is heightened by variability in the values placed
on benefits and risks.
In December 2008, the FDA reviewed the risks and benefits of inhaled long-acting beta-agonists for the treatment of asthma in adults and children. Dr. Judith Kramer writes that the challenge of protecting the public's health is heightened by variability in the values placed on benefits and risks.
The New England Journal Of Medicine